Last reviewed · How we verify
68Ga-HTK03149
68Ga-HTK03149 is a radiolabeled compound used for imaging purposes, particularly in oncology.
68Ga-HTK03149 is a radiolabeled compound used for imaging purposes, particularly in oncology. Used for Imaging of neuroendocrine tumors and other cancers expressing somatostatin receptors.
At a glance
| Generic name | 68Ga-HTK03149 |
|---|---|
| Sponsor | British Columbia Cancer Agency |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This drug is designed to bind to specific targets in tumors, allowing for detailed imaging through positron emission tomography (PET). The gallium-68 isotope emits positrons, which can be detected to create high-resolution images of tumor locations and characteristics.
Approved indications
- Imaging of neuroendocrine tumors and other cancers expressing somatostatin receptors
Common side effects
- Nausea
- Vomiting
Key clinical trials
- 177Lu-HTK03170 in mCRPC With PSMA Positive Disease (PHASE1, PHASE2)
- Dynamic Whole Body PET/ MRI
- 68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 68Ga-HTK03149 CI brief — competitive landscape report
- 68Ga-HTK03149 updates RSS · CI watch RSS
- British Columbia Cancer Agency portfolio CI